News
-
-
-
PRESS RELEASE
Axiodis CRO, the French subsidiary of the Oxurion Group, announces a dual AI-driven strategic initiative to transform clinical trials
Axiodis CRO, a subsidiary of Oxurion NV, leverages AI to enhance clinical trials with digital twins for disease simulation and AI modules integrated into Exagis eCRF solution for improved data quality and workflow efficiency -
-
PRESS RELEASE
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
Oxurion NV receives transparency notification from Atlas Special Opportunities II, LLC regarding change in shareholding. Oxurion specializes in acquiring majority stakes in European pharmaceutical subcontractors -
-
-
-
PRESS RELEASE
Oxurion Receives Transparency Notifications from UBS Group AG
Oxurion NV received transparency notifications from UBS Group AG regarding share holdings, in compliance with Belgian Transparency legislation. The company is a biopharmaceutical group focusing on therapeutic innovation and clinical research technologies -